Study demonstrates an increase in HDL and lower lipoprotein(a) in type 2 diabetes patients with this nutritional intervention
- Posted by Denise
- on Oct, 18, 2020
- in Blog Posts
- Blog No Comments.
According to a study published inĀ Complementary Therapies in Medicine, another application can be added to this list: addressing dyslipidemia in patients with type II diabetes. Researchers demonstrated that curcuminoid supplementation can reduce lipoprotein(a) and increase HDL-C, which may reduce the risk of a cardiovascular event in these patients.
This study included a total of 82 patients with type II diabetes, 18 to 65 years of age. Each patient took either 1000 mg of standardized curcuminĀ or a placebo for 12 weeks. Baseline lab testing included serum triglycerides, total cholesterol, HDL-C, non-HDL-C, and lipoprotein(a). At the end of the 12 weeks there was a significant reduction of serum lipoprotein(a) and an increase in HDL-C concentrations only seen in the curcuminoid group. There were no significant changes in total cholesterol, LDL-C, and triglycerides in either group.
This is an interesting study since the ability to influence lipoprotein(a) is very limited. Niacin is one of the only natural agents that can significantly reduce lipoprotein(a); however, it is not effective for everyone.
Health care providers have many tools today to assess cardiovascular health and support the body’s physiology, and it is essential to perform a thorough assessment of these patients. This may include looking at lipid fractionation profiles, chronic inflammatory markers (ferritin, hs-CRP, fibrinogen), nutrient markers (magnesium, potassium, selenium, copper, folate, B12, B6, zinc, and calcium), fat soluble nutrients (vitamins A, D, E & K, and CoQ10), oxidative stress factors (homocysteine, insulin, and lipid peroxidases), heavy metals, and fatty acid profiles. A successful treatment approach should include investigation into these various factors.
Source: Panahi Y, Khalili N et al. Curcuminoids modify lipid profile in type 2 diabetes mellitus: A randomized control trial. Complementary Therapies in Medicine. 2017 August;22:1-5.
Comments & Responses
Categories
Archives
- June 2022
- May 2022
- April 2022
- March 2022
- February 2022
- January 2022
- December 2021
- November 2021
- October 2021
- September 2021
- August 2021
- July 2021
- June 2021
- May 2021
- April 2021
- March 2021
- February 2021
- November 2020
- October 2020
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012